Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5403688 | 1.00 | EGFR (0.31) | EGFR | |
| SCHEMBL7572272 | 0.92 | EGFR (0.31) | EGFR | |
| SCHEMBL5397197 | 0.92 | ALDH1A1 (0.36) | EGFR | |
| SCHEMBL5397192 | 0.92 | ALDH1A1 (0.36) | EGFR | |
| SCHEMBL5412149 | 0.89 | EGFR (0.40) | EGFR | |
| SCHEMBL5412146 | 0.89 | EGFR (0.40) | EGFR | |
| SCHEMBL5406525 | 0.88 | RARB (0.32) | — | |
| SCHEMBL5406530 | 0.88 | RARB (0.32) | — | |
| SCHEMBL5394950 | 0.86 | TNFSF11 (0.42) | EGFR | |
| SCHEMBL5394948 | 0.86 | TNFSF11 (0.42) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208142-B2 | Indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2007-04-24 | — | — | US | claimed |
| EP-1466892-A1 | Novel indanylidene compounds | Symrise GmbH & Co. KG (DE) | 2004-10-13 | — | — | EP | claimed |
| EP-1341752-B1 | NOVEL INDANYLIDENE COMPOUNDS | SYMRISE GMBH & CO KG (DE) | 2004-08-04 | — | — | EP | claimed |
| CN-1473146-A | Novel indanylidene compounds | ��������ķ������ | 2004-02-04 | — | — | CN | claimed |
| US-20020143203-A1 | Novel indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2002-10-03 | — | — | US | claimed |
| US-20070185057-A1 | Novel Indanone Compounds | SYMRISE GMBH & CO. KG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-7208142-B2 | Indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2007-04-24 | — | — | US | disclosed |
| EP-1466892-A1 | Novel indanylidene compounds | Symrise GmbH & Co. KG (DE) | 2004-10-13 | — | — | EP | disclosed |
| EP-1341752-B1 | NOVEL INDANYLIDENE COMPOUNDS | SYMRISE GMBH & CO KG (DE) | 2004-08-04 | — | — | EP | disclosed |
| CN-1473146-A | Novel indanylidene compounds | ��������ķ������ | 2004-02-04 | — | — | CN | disclosed |
| US-20020143203-A1 | Novel indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185057-A1 | Novel Indanone Compounds | CUTA, NISCH, TYR | EGFR 1186/4885 |
| US-20020143203-A1 | Novel indanylidene compounds | CUTA, NISCH, ERCC4 | EGFR 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.